| Year |
Citation |
Score |
| 2024 |
Taniguchi H, Chakraborty S, Takahashi N, Banerjee A, Caeser R, Zhan YA, Tischfield SE, Chow A, Nguyen EM, Villalonga ÁQ, Manoj P, Shah NS, Rosario S, Hayatt O, Qu R, ... ... Rudin CM, et al. ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Science Advances. 10: eado4618. PMID 39331709 DOI: 10.1126/sciadv.ado4618 |
0.348 |
|
| 2024 |
Murciano-Goroff YR, Hui AB, Araujo Filho JA, Hamilton EG, Chabon JJ, Moding EJ, Bonilla RF, Lebow ES, Gomez D, Rimner A, Ginsberg MS, Offin M, Kundra R, Allaj V, Norton L, ... ... Rudin CM, et al. Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer. Jco Precision Oncology. 8: e2400216. PMID 39231375 DOI: 10.1200/PO.24.00216 |
0.361 |
|
| 2024 |
Redin E, Sridhar H, Zhan YA, Pereira Mello B, Zhong H, Durani V, Sabet A, Manoj P, Linkov I, Qiu J, Koche RP, de Stanchina E, Astorkia M, Betel D, Quintanal-Villalonga Á, ... Rudin CM, et al. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. Journal of Hematology & Oncology. 17: 58. PMID 39080761 DOI: 10.1186/s13045-024-01572-3 |
0.338 |
|
| 2024 |
Elkrief A, Montesion M, Sivakumar S, Hale C, Bowman AS, Begüm Bektaş A, Bradic M, Kang W, Chan E, Gogia P, Manova-Todorova K, Mata DA, Egger JV, Rizvi H, Socci ND, ... ... Rudin CM, et al. Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301488. PMID 39038258 DOI: 10.1200/JCO.23.01488 |
0.36 |
|
| 2024 |
He T, Xiao L, Qiao Y, Klingbeil O, Young E, Wu XS, Mannan R, Mahapatra S, Redin E, Cho H, Bao Y, Kandarpa M, Ching-Yi Tien J, Wang X, Eyunni S, ... ... Rudin CM, et al. Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. Cancer Cell. PMID 39029462 DOI: 10.1016/j.ccell.2024.06.006 |
0.313 |
|
| 2024 |
Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, ... ... Rudin CM, et al. Imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. The Lancet. Oncology. PMID 38950555 DOI: 10.1016/S1470-2045(24)00249-3 |
0.617 |
|
| 2024 |
Choudhury NJ, Lai WV, Makhnin A, Heller G, Eng J, Li B, Preeshagul I, Santini FC, Offin M, Ng K, Paik P, Larsen C, Ginsberg MS, Lau Y, Zhang X, ... ... Rudin CM, et al. A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38940666 DOI: 10.1158/1078-0432.CCR-23-3383 |
0.377 |
|
| 2024 |
Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O'Brien C, Paz-Ares L, Goldman JW, Garassino MC, Gay CM, Heymach JV, Jiang H, Barrett JC, Stewart RA, Lai Z, ... ... Rudin CM, et al. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Molecular Cancer. 23: 115. PMID 38811992 DOI: 10.1186/s12943-024-02014-x |
0.307 |
|
| 2024 |
Tringale KR, Skakodub A, Egger J, Eichholz J, Yu Y, Gomez D, Rimner A, Li B, Yamada Y, Wilcox J, Moss N, Imber BS, Rekhtman N, Baine MK, Rudin CM, et al. Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases. Jco Precision Oncology. 8: e2300470. PMID 38691815 DOI: 10.1200/PO.23.00470 |
0.307 |
|
| 2024 |
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, et al. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2302110. PMID 38648575 DOI: 10.1200/JCO.23.02110 |
0.327 |
|
| 2024 |
Hiatt JB, Doebley AL, Arnold HU, Adil M, Sandborg H, Persse TW, Ko M, Wu F, Quintanal Villalonga A, Santana-Davila R, Eaton K, Dive C, Rudin CM, Thomas A, Houghton AM, et al. Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions. Science Advances. 10: eadk2082. PMID 38598634 DOI: 10.1126/sciadv.adk2082 |
0.351 |
|
| 2024 |
Pillai R, LeBoeuf SE, Hao Y, New C, Blum JLE, Rashidfarrokhi A, Huang SM, Bahamon C, Wu WL, Karadal-Ferrena B, Herrera A, Ivanova E, Cross M, Bossowski JP, Ding H, ... ... Rudin CM, et al. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in mutant lung cancer. Science Advances. 10: eadm9859. PMID 38536921 DOI: 10.1126/sciadv.adm9859 |
0.657 |
|
| 2024 |
Taniguchi H, Chavan SS, Chow A, Chan JM, Mukae H, Rudin CM, Sen T. Role of CD38 in anti-tumor immunity of small cell lung cancer. Frontiers in Immunology. 15: 1348982. PMID 38533509 DOI: 10.3389/fimmu.2024.1348982 |
0.333 |
|
| 2024 |
Cai L, Gao Y, DeBerardinis R, Chen T, Winslow M, Xiao G, Rudin C, Oliver T, Minna J, Xie Y. A Lung Cancer Mouse Model Database. Biorxiv : the Preprint Server For Biology. PMID 38464291 DOI: 10.1101/2024.02.28.582577 |
0.319 |
|
| 2024 |
Catozzi A, Peiris-Pagès M, Humphrey S, Revill M, Morgan D, Roebuck J, Chen Y, Davies-Williams B, Lallo A, Galvin M, Pearce SP, Kerr A, Priest L, Foy V, Carter M, ... ... Rudin CM, et al. Functional Characterisation of the ATOH1 Molecular Subtype Indicates a Pro-Metastatic Role in Small Cell Lung Cancer. Biorxiv : the Preprint Server For Biology. PMID 38405859 DOI: 10.1101/2024.02.16.580247 |
0.363 |
|
| 2024 |
Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, Gayevskiy V, Elhossiny AM, Srivastava MK, Patil NS, Smith KA, Jesudason R, Chan C, Chang PS, Fernandez M, ... ... Rudin CM, et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. PMID 38366589 DOI: 10.1016/j.ccell.2024.01.010 |
0.317 |
|
| 2024 |
Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, ... ... Rudin CM, et al. First-in-human imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate. Medrxiv : the Preprint Server For Health Sciences. PMID 38260492 DOI: 10.1101/2024.01.10.24301109 |
0.637 |
|
| 2023 |
Odintsov I, Makarem M, Nishino M, Bachert SE, Zhang T, LoPiccolo J, Paweletz CP, Gokhale PC, Ivanova E, Saldanha A, Rudin CM, Lockwood WW, Ladanyi M, Somwar R, Jänne PA, et al. Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 38154514 DOI: 10.1016/j.jtho.2023.12.019 |
0.349 |
|
| 2023 |
Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, et al. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301363. PMID 37976444 DOI: 10.1200/JCO.23.01363 |
0.323 |
|
| 2023 |
Li Z, Zhuang X, Pan CH, Yan Y, Thummalapalli R, Hallin J, Torborg SR, Singhal A, Chang JC, Manchado E, Dow LE, Yaeger R, Christensen JG, Lowe SW, Rudin CM, et al. Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. Cancer Discovery. PMID 37931288 DOI: 10.1158/2159-8290.CD-23-0289 |
0.396 |
|
| 2023 |
Zavitsanou AM, Pillai R, Hao Y, Wu WL, Bartnicki E, Karakousi T, Rajalingam S, Herrera A, Karatza A, Rashidfarrokhi A, Solis S, Ciampricotti M, Yeaton AH, Ivanova E, Wohlhieter CA, ... ... Rudin CM, et al. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Cell Reports. 42: 113295. PMID 37889752 DOI: 10.1016/j.celrep.2023.113295 |
0.629 |
|
| 2023 |
Li Z, Zhuang X, Pan CH, Yan Y, Thummalapalli R, Hallin J, Torborg S, Singhal A, Chang JC, Manchado E, Dow LE, Yaeger R, Christensen JG, Lowe SW, Rudin CM, et al. Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. Biorxiv : the Preprint Server For Biology. PMID 37808711 DOI: 10.1101/2023.09.29.560194 |
0.396 |
|
| 2023 |
Elkrief A, Riccuiti B, Alessi JV, Fei T, Kalvin HL, Egger JV, Rizvi H, Thummalapalli R, Lamberti G, Plodkowski A, Hellmann MD, Kris MG, Arcila ME, Baine MK, Rudin CM, et al. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. The Oncologist. PMID 37589215 DOI: 10.1093/oncolo/oyad197 |
0.337 |
|
| 2023 |
Gentzler RD, Villaruz LC, Rhee JC, Horton B, Mock J, Hanley M, Kim K, Rudek MA, Phelps MA, Carducci MA, Piekarz R, Park KS, Bullock TN, Rudin CM. Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. The Oncologist. PMID 37555284 DOI: 10.1093/oncolo/oyad221 |
0.373 |
|
| 2023 |
Pillai R, LeBoeuf SE, Hao Y, New C, Blum JLE, Rashidfarrokhi A, Huang SM, Bahamon C, Wu WL, Karadal-Ferrena B, Herrera A, Ivanova E, Cross M, Bossowski JP, Ding H, ... ... Rudin CM, et al. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in mutant lung cancer. Biorxiv : the Preprint Server For Biology. PMID 37425844 DOI: 10.1101/2023.06.27.546750 |
0.644 |
|
| 2023 |
Chakraborty S, Coleman C, Manoj P, Demircioglu D, Shah N, de Stanchina E, Rudin CM, Hasson D, Sen T. De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37382635 DOI: 10.1158/1078-0432.CCR-23-0471 |
0.361 |
|
| 2023 |
Rudin CM, Reck M, Johnson ML, Blackhall F, Hann CL, Yang JC, Bailis JM, Bebb G, Goldrick A, Umejiego J, Paz-Ares L. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. Journal of Hematology & Oncology. 16: 66. PMID 37355629 DOI: 10.1186/s13045-023-01464-y |
0.303 |
|
| 2023 |
Rudin CM, Balli D, Lai WV, Richards AL, Nguyen E, Egger JV, Choudhury NJ, Sen T, Chow A, Poirier JT, Geese WJ, Hellmann MD, Forslund A. Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 37210008 DOI: 10.1016/j.jtho.2023.05.008 |
0.642 |
|
| 2023 |
Deng J, Peng DH, Fenyo D, Yuan H, Lopez A, Levin DS, Meynardie M, Quinteros M, Ranieri M, Sahu S, Lau SCM, Shum E, Velcheti V, Punekar SR, Rekhtman N, ... ... Rudin CM, et al. metabolomics identifies CD38 as an emergent vulnerability in -mutant lung cancer. Biorxiv : the Preprint Server For Biology. PMID 37131623 DOI: 10.1101/2023.04.18.537350 |
0.608 |
|
| 2023 |
Glasner A, Rose SA, Sharma R, Gudjonson H, Chu T, Green JA, Rampersaud S, Valdez IK, Andretta ES, Dhillon BS, Schizas M, Dikiy S, Mendoza A, Hu W, Wang ZM, ... ... Rudin CM, et al. Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies. Nature Immunology. PMID 37127830 DOI: 10.1038/s41590-023-01504-2 |
0.309 |
|
| 2023 |
Tendler S, Rudin CM. Tarlatamab-New Star on the Horizon for Small-Cell Lung Cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300148. PMID 37098228 DOI: 10.1200/JCO.23.00148 |
0.332 |
|
| 2023 |
Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, Brentjens RJ. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. The Journal of Clinical Investigation. PMID 36951942 DOI: 10.1172/JCI166028 |
0.317 |
|
| 2023 |
Zhang S, Kim KB, Huang Y, Kim DW, Kim B, Ko KP, Zou G, Zhang J, Jun S, Kirk NA, Hwang YE, Ban YH, Chan JM, Rudin CM, Park KS, et al. CRACD, a gatekeeper restricting proliferation, heterogeneity, and immune evasion of small cell lung cancer. Biorxiv : the Preprint Server For Biology. PMID 36824957 DOI: 10.1101/2023.02.15.528365 |
0.387 |
|
| 2022 |
Offin M, Sauter JL, Tischfield SE, Egger JV, Chavan S, Shah NS, Manoj P, Ventura K, Allaj V, de Stanchina E, Travis W, Ladanyi M, Rimner A, Rusch VW, Adusumilli PS, ... ... Rudin CM, et al. Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library. Genome Medicine. 14: 127. PMID 36380343 DOI: 10.1186/s13073-022-01129-4 |
0.526 |
|
| 2022 |
Quintanal-Villalonga Á, Chan JM, Masilionis I, Gao VR, Xie Y, Allaj V, Chow A, Poirier JT, Pe'er D, Rudin CM, Mazutis L. Protocol to dissociate, process, and analyze the human lung tissue using single-cell RNA-seq. Star Protocols. 3: 101776. PMID 36313536 DOI: 10.1016/j.xpro.2022.101776 |
0.579 |
|
| 2022 |
Paik PK, Fan PD, Qeriqi B, Namakydoust A, Daly B, Ahn L, Kim R, Plodkowski A, Ni A, Chang J, Fanaroff R, Ladanyi M, de Stanchina E, Rudin CM. Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 36240971 DOI: 10.1016/j.jtho.2022.09.225 |
0.367 |
|
| 2022 |
Chemi F, Pearce SP, Clipson A, Hill SM, Conway AM, Richardson SA, Kamieniecka K, Caeser R, White DJ, Mohan S, Foy V, Simpson KL, Galvin M, Frese KK, Priest L, ... ... Rudin CM, et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nature Cancer. PMID 35941262 DOI: 10.1038/s43018-022-00415-9 |
0.617 |
|
| 2022 |
Febres Aldana CA, Chang JC, Ptashkin R, Wang Y, Gedvilaite E, Baine MK, Travis WD, Ventura K, Bodd F, Yu HA, Quintanal-Villalonga A, Lai WV, Egger JV, Offin M, Ladanyi M, ... Rudin CM, et al. Rb tumor suppressor in small cell lung cancer: Combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35792876 DOI: 10.1158/1078-0432.CCR-22-1115 |
0.385 |
|
| 2022 |
Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Roman MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G, Fishinevich E, Meng Y, Wong EWP, Yan J, Giff E, ... ... Rudin CM, et al. PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry. Cancer Discovery. PMID 35789380 DOI: 10.1158/2159-8290.CD-21-1671 |
0.327 |
|
| 2022 |
Baine MK, Febres-Aldana CA, Chang JC, Jungbluth AA, Sethi S, Antonescu CR, Travis WD, Hsieh MS, Roh MS, Homer RJ, Ladanyi M, Egger JV, Lai WV, Rudin CM, Rekhtman N. POU2F3 in SCLC: Clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 35760287 DOI: 10.1016/j.jtho.2022.06.004 |
0.312 |
|
| 2022 |
Korsen JA, Gutierrez JA, Tully KM, Carter LM, Samuels ZV, Khitrov S, Poirier JT, Rudin CM, Chen Y, Morris MJ, Bodei L, Pillarsetty N, Lewis JS. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 119: e2203820119. PMID 35759660 DOI: 10.1073/pnas.2203820119 |
0.576 |
|
| 2022 |
Nguyen EM, Taniguchi H, Chan JM, Zhan YA, Chen X, Qiu J, de Stanchina E, Allaj V, Shah NS, Uddin F, Manoj P, Liu M, Cai SF, Levine R, Quintanal-Villalonga A, ... ... Rudin CM, et al. Targeting LSD1 rescues MHC class I antigen presentation and overcomes PD-L1 blockade resistance in small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 35691495 DOI: 10.1016/j.jtho.2022.05.014 |
0.342 |
|
| 2022 |
Rimner A, Lai WV, Califano R, Jabbour SK, Rudin CM, Faivre-Finn C, Cho BC, Kato T, Yu J, Chafin W, Yu L, Zhao B, Byers L. Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 35613997 DOI: 10.1016/j.cllc.2022.04.005 |
0.309 |
|
| 2022 |
Mukherjee S, Bandlamudi C, Hellmann MD, Kemel Y, Drill E, Rizvi H, Tkachuk K, Khurram A, Walsh MF, Zauderer MG, Mandelker D, Topka S, Zehir A, Srinivasan P, Esai Selvan M, ... ... Rudin CM, et al. Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35477182 DOI: 10.1158/1055-9965.EPI-21-1287 |
0.306 |
|
| 2022 |
Caeser R, Egger JV, Chavan S, Socci ND, Jones CB, Kombak FE, Asher M, Roehrl MH, Shah NS, Allaj V, Manoj P, Tischfield SE, Kulick A, Meneses M, Iacobuzio-Donahue CA, ... ... Rudin CM, et al. Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. Nature Communications. 13: 2144. PMID 35440124 DOI: 10.1038/s41467-022-29794-4 |
0.644 |
|
| 2022 |
Korsen JA, Kalidindi TM, Khitrov S, Samuels ZV, Chakraborty G, Gutierrez JA, Poirier JT, Rudin CM, Chen Y, Morris MJ, Pillarsetty N, Lewis JS. Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 35058323 DOI: 10.2967/jnumed.121.263221 |
0.554 |
|
| 2022 |
Tully KM, Tendler S, Carter LM, Sharma SK, Samuels ZV, Mandleywala K, Korsen JA, Delos Reyes AM, Piersigilli A, Travis WD, Sen T, Pillarsetty N, Poirier JT, Rudin CM, Lewis JS. Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35046060 DOI: 10.1158/1078-0432.CCR-21-1533 |
0.663 |
|
| 2021 |
Luu AP, Yao Z, Ramachandran S, Azzopardi SA, Miles LA, Schneider WM, Hoffmann HH, Bozzacco L, Garcia G, Gong D, Damoiseaux R, Tang H, Morizono K, Rudin CM, Sun R, et al. A CRISPR Activation Screen Identifies an Atypical Rho GTPase That Enhances Zika Viral Entry. Viruses. 13. PMID 34834920 DOI: 10.3390/v13112113 |
0.547 |
|
| 2021 |
Quintanal-Villalonga A, Taniguchi H, Hao Y, Chow A, Zhan YA, Chavan SS, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Offin M, Ciampricotti M, Ray-Kirton J, Egger J, ... ... Rudin CM, et al. Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy. Cancer Research. PMID 34815254 DOI: 10.1158/0008-5472.CAN-21-2964 |
0.674 |
|
| 2021 |
Caeser R, Hulton C, Costa E, Durani V, Little M, Chen X, Tischfield SE, Asher M, Kombak FE, Chavan SS, Shah NS, Ciampricotti M, de Stanchina E, Poirier JT, Rudin CM, et al. MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. Iscience. 24: 103224. PMID 34712921 DOI: 10.1016/j.isci.2021.103224 |
0.653 |
|
| 2021 |
Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Ciampricotti M, Chow A, Offin M, Ray-Kirton J, ... ... Rudin CM, et al. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. Journal of Hematology & Oncology. 14: 170. PMID 34656143 DOI: 10.1186/s13045-021-01186-z |
0.381 |
|
| 2021 |
Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, ... ... Rudin CM, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. PMID 34653364 DOI: 10.1016/j.ccell.2021.09.008 |
0.647 |
|
| 2021 |
Concepcion CP, Ma S, LaFave LM, Bhutkar A, Liu M, DeAngelo LP, Kim JY, Del Priore I, Schoenfeld AJ, Miller M, Kartha VK, Westcott PMK, Sanchez-Rivera FJ, Meli K, Gupta M, ... ... Rudin CM, et al. SMARCA4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. Cancer Discovery. PMID 34561242 DOI: 10.1158/2159-8290.CD-21-0248 |
0.347 |
|
| 2021 |
Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, Xie Y, Ishizawa K, Osmanbeyoglu HU, Lyu Y, Roper N, ... ... Rudin CM, et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. PMID 34388376 DOI: 10.1016/j.ccell.2021.07.006 |
0.315 |
|
| 2021 |
Ciampricotti M, Karakousi T, Richards AL, Quintanal-Villalonga A, Karatza A, Caeser R, Costa EA, Allaj V, Manoj P, Spainhower KB, Kombak FE, Sanchez-Rivera FJ, Jaspers JE, Zavitsanou AM, Maddalo D, ... ... Rudin CM, et al. Rlf-Mycl gene fusion drives tumorigenesis and metastasis in a mouse model of small cell lung cancer. Cancer Discovery. PMID 34344693 DOI: 10.1158/2159-8290.CD-21-0441 |
0.652 |
|
| 2021 |
Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Manoj P, Donoghue MTA, Won HH, Chan JM, Ciampricotti M, Chow A, Offin M, Chang JC, ... ... Rudin CM, et al. Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discovery. PMID 34155000 DOI: 10.1158/2159-8290.CD-20-1863 |
0.642 |
|
| 2021 |
Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, Poirier JT, Peng D, Bulatovic M, Mukhopadhyay S, Silver H, Papadopoulos E, Pyon V, Thakurdin C, Han H, ... ... Rudin CM, et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nature Cancer. 2: 503-514. PMID 34142094 DOI: 10.1038/s43018-021-00208-6 |
0.61 |
|
| 2021 |
Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, ... ... Rudin CM, et al. Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. Cancer Cell. PMID 34115989 DOI: 10.1016/j.ccell.2021.05.006 |
0.593 |
|
| 2021 |
Norton JP, Augert A, Eastwood E, Basom R, Rudin CM, MacPherson D. Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas. Genes & Development. PMID 34016692 DOI: 10.1101/gad.348316.121 |
0.366 |
|
| 2021 |
Jayawardena N, Miles LA, Burga LN, Rudin C, Wolf M, Poirier JT, Bostina M. N-Linked Glycosylation on Anthrax Toxin Receptor 1 Is Essential for Seneca Valley Virus Infection. Viruses. 13. PMID 33924774 DOI: 10.3390/v13050769 |
0.546 |
|
| 2021 |
Sharma SK, Adumeau P, Keinänen O, Sisodiya V, Sarvaiya H, Tchelepi R, Korsen JA, Pourat J, Edwards KJ, Ragupathi A, Hamdy O, Saunders LR, Rudin CM, Poirier JT, Lewis JS, et al. Synthesis and Comparative Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. Bioconjugate Chemistry. PMID 33835770 DOI: 10.1021/acs.bioconjchem.1c00121 |
0.587 |
|
| 2021 |
Choudhury NJ, Schoenfeld AJ, Flynn J, Falcon CJ, Rizvi H, Rudin CM, Kris MG, Arcila ME, Heller G, Yu HA, Ladanyi M, Riely GJ. Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33685865 DOI: 10.1158/1078-0432.CCR-20-4650 |
0.326 |
|
| 2021 |
Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG. Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss-driven Tumorigenesis. Molecular Cancer Therapeutics. 20: 450. PMID 33547247 DOI: 10.1158/1535-7163.MCT-20-1027 |
0.517 |
|
| 2021 |
Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nature Reviews. Disease Primers. 7: 3. PMID 33446664 DOI: 10.1038/s41572-020-00235-0 |
0.37 |
|
| 2020 |
Hulton CH, Costa EA, Shah NS, Quintanal-Villalonga A, Heller G, de Stanchina E, Rudin CM, Poirier JT. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid functional genomics. Nature Cancer. 1: 359-369. PMID 33345196 DOI: 10.1038/s43018-020-0040-8 |
0.615 |
|
| 2020 |
Hoffmann HH, Schneider WM, Rozen-Gagnon K, Miles LA, Schuster F, Razooky B, Jacobson E, Wu X, Yi S, Rudin CM, MacDonald MR, McMullan LK, Poirier JT, Rice CM. TMEM41B Is a Pan-flavivirus Host Factor. Cell. PMID 33338421 DOI: 10.1016/j.cell.2020.12.005 |
0.506 |
|
| 2020 |
Wohlhieter CA, Richards AL, Uddin F, Hulton CH, Quintanal-Villalonga À, Martin A, de Stanchina E, Bhanot U, Asher M, Shah NS, Hayatt O, Buonocore DJ, Rekhtman N, Shen R, Arbour KC, ... ... Rudin CM, et al. Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Reports. 33: 108444. PMID 33264619 DOI: 10.1016/j.celrep.2020.108444 |
0.604 |
|
| 2020 |
Hoffmann HH, Schneider WM, Rozen-Gagnon K, Miles LA, Schuster F, Razooky B, Jacobson E, Wu X, Yi S, Rudin CM, MacDonald MR, McMullan LK, Poirier JT, Rice CM. TMEM41B is a pan-flavivirus host factor. Biorxiv : the Preprint Server For Biology. PMID 33052348 DOI: 10.1101/2020.10.09.334128 |
0.506 |
|
| 2020 |
Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth A, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, ... ... Rudin CM, et al. Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33011388 DOI: 10.1016/j.jtho.2020.09.009 |
0.608 |
|
| 2020 |
Offin M, Luo J, Guo R, Lyo JK, Falcon C, Dienstag J, Wilkins O, Chang J, Rudin CM, Riely G, Rekhtman N, Arcila ME, Heller G, Ladanyi M, Li BT, et al. CNS Metastases in Patients With Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. Jco Precision Oncology. 4. PMID 32923895 DOI: 10.1200/PO.20.00098 |
0.308 |
|
| 2020 |
Shibata M, Ooki A, Inokawa Y, Sadhukhan P, Ugurlu MT, Izumchenko E, Munari E, Bogina G, Rudin CM, Gabrielson E, Singh A, Hoque MO. Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy. Molecular Cancer Therapeutics. PMID 32847981 DOI: 10.1158/1535-7163.Mct-20-0024 |
0.332 |
|
| 2020 |
Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, Hartmann GG, Smith OC, Kim JY, Evans KV, Hudson A, Ashenberg O, Porter CBM, Bejnood A, Subramanian A, ... ... Rudin CM, et al. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell. PMID 32707077 DOI: 10.1016/J.Ccell.2020.06.012 |
0.647 |
|
| 2020 |
Kern JA, Kim J, Foster DG, Mishra R, Gardner EE, Poirier JT, Rivard C, Yu H, Finigan JH, Dowlati A, Rudin CM, Tan AC. Role of mTOR as an essential kinase in SCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32599072 DOI: 10.1016/J.Jtho.2020.05.026 |
0.618 |
|
| 2020 |
Drapkin BJ, Rudin CM. Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harbor Perspectives in Medicine. PMID 32513672 DOI: 10.1101/cshperspect.a038240 |
0.328 |
|
| 2020 |
Taniguchi H, Sen T, Rudin CM. Targeted Therapies and Biomarkers in Small Cell Lung Cancer. Frontiers in Oncology. 10: 741. PMID 32509576 DOI: 10.3389/fonc.2020.00741 |
0.362 |
|
| 2020 |
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000793. PMID 32468956 DOI: 10.1200/Jco.20.00793 |
0.329 |
|
| 2020 |
Morgensztern D, Johnson M, Rudin CM, Rossi M, Lazarov M, Brickman D, Fong A. SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. Lung Cancer (Amsterdam, Netherlands). 145: 126-131. PMID 32438272 DOI: 10.1016/j.lungcan.2020.04.017 |
0.341 |
|
| 2020 |
Offin M, Shaverdian N, Rimner A, Lobaugh S, Shepherd AF, Simone CB, Gelblum DY, Wu AJ, Lee N, Kris MG, Rudin CM, Zhang Z, Hellmann MD, Chaft JE, Gomez DR. Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 32361014 DOI: 10.1016/J.Radonc.2020.04.047 |
0.305 |
|
| 2020 |
Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, ... ... Rudin CM, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discovery. PMID 32213539 DOI: 10.1158/2159-8290.Cd-20-0215 |
0.641 |
|
| 2020 |
Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Triparna S, Rudin CM. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nature Reviews. Clinical Oncology. PMID 32152485 DOI: 10.1038/s41571-020-0340-z |
0.328 |
|
| 2020 |
Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, Jiao X, Xie W, Kong X, Vaz M, Li H, Cai Y, Xia L, Huang P, Rodgers K, ... ... Rudin CM, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. PMID 32103175 DOI: 10.1038/S41586-020-2054-X |
0.317 |
|
| 2020 |
Laughney AM, Hu J, Campbell NR, Bakhoum SF, Setty M, Lavallée VP, Xie Y, Masilionis I, Carr AJ, Kottapalli S, Allaj V, Mattar M, Rekhtman N, Xavier JB, Mazutis L, ... ... Rudin CM, et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nature Medicine. PMID 32042191 DOI: 10.1038/S41591-019-0750-6 |
0.636 |
|
| 2020 |
Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, ... ... Rudin CM, et al. New approaches to small cell lung cancer therapy : from the laboratory to the clinic. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32018053 DOI: 10.1016/J.Jtho.2020.01.016 |
0.658 |
|
| 2020 |
Paik PK, Kim RK, Ahn L, Plodkowski AJ, Ni A, Donoghue MTA, Jonsson P, Villalona-Calero M, Ng K, McFarland D, Fiore JJ, Iqbal A, Eng J, Kris MG, Rudin CM. A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31919132 DOI: 10.1158/1078-0432.CCR-19-3060 |
0.353 |
|
| 2020 |
Lai WV, Egger JV, Rizvi H, Richards AL, Beras A, Baine MK, Hsieh M, Chang JC, Rekhtman N, Plodkowski AJ, Ginsberg MS, Kris MG, Hellmann MD, Sen T, Poirier JT, ... Rudin CM, et al. Molecular subtypes and clinical outcomes to initial systemic treatment in patients with small cell lung cancer. Journal of Clinical Oncology. 38: 9018-9018. DOI: 10.1200/Jco.2020.38.15_Suppl.9018 |
0.559 |
|
| 2020 |
Brannon AR, Jayakumaran G, Diosdado M, Hu Y, Razumova A, Meng F, Lebow E, Patel J, Johnson I, Srinivasan P, Hasan M, Dix J, Syed A, Houck-Loomis B, Li BT, ... Rudin C, et al. Abstract PR08: Validation and clinical implementation of MSK-ACCESS, an ultra-deep sequencing assay for noninvasive somatic mutation profiling Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-Pr08 |
0.367 |
|
| 2020 |
Hulton CH, Costa EA, Shah NS, Quintanal-Villalonga A, Heller G, de Stanchina E, Rudin CM, Poirier JT. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics Nature Cancer. 1: 359-369. DOI: 10.1038/S43018-020-0040-8 |
0.609 |
|
| 2020 |
Prabhu A, Scott K, Stewart P, Grass D, Fernandez M, Koomen J, Bannister T, Sumner S, Rudin C, Denicola G, Cleveland J, Haura E. A22 Integrated Proteometabolomic Analysis Reveals Metabolic Vulnerabilities in Small-Cell Lung Cancer Journal of Thoracic Oncology. 15: S19. DOI: 10.1016/J.Jtho.2019.12.051 |
0.408 |
|
| 2019 |
Shaverdian N, Offin MD, Rimner A, Shepherd AF, Wu AJ, Rudin CM, Hellmann MD, Chaft JE, Gomez DR. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 144: 101-104. PMID 31786421 DOI: 10.1016/j.radonc.2019.11.015 |
0.309 |
|
| 2019 |
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, et al. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31506387 DOI: 10.1158/1078-0432.CCR-19-1133 |
0.318 |
|
| 2019 |
Devarakonda S, Sankararaman S, Herzog B, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D. Circulating Tumor DNA Profiling in Small Cell Lung Cancer Identifies Potentially Targetable Alterations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31300452 DOI: 10.1158/1078-0432.Ccr-19-0879 |
0.612 |
|
| 2019 |
Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A, Penson A, Hellmann MD, Arcila ME, Ladanyi M, Pe'er D, Kris MG, ... Rudin CM, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31228622 DOI: 10.1016/j.jtho.2019.06.002 |
0.307 |
|
| 2019 |
Laird J, Lok BH, Carney B, Kossatz S, de Stanchina E, Reiner T, Poirier JT, Rudin CM. PET Imaging of a [F]-radiolabeled PARP Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in Small Cell Lung Cancer Patient-Derived Xenografts. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31195178 DOI: 10.1016/J.Jtho.2019.05.032 |
0.63 |
|
| 2019 |
Offin M, Guo R, Wu SL, Sabari J, Land JD, Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, Liu D, Riely GJ, Hellmann MD, Benayed R, Arcila M, ... ... Rudin CM, et al. Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. Jco Precision Oncology. 3. PMID 31192313 DOI: 10.1200/PO.18.00386 |
0.307 |
|
| 2019 |
Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, et al. Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews. Cancer. PMID 31175338 DOI: 10.1038/S41568-019-0164-2 |
0.621 |
|
| 2019 |
Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews. Cancer. PMID 30926931 DOI: 10.1038/S41568-019-0133-9 |
0.654 |
|
| 2019 |
Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, ... ... Rudin CM, et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30891595 DOI: 10.1093/Annonc/Mdz046 |
0.322 |
|
| 2019 |
Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, et al. Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30831205 DOI: 10.1016/J.Jtho.2018.12.038 |
0.612 |
|
| 2019 |
Augert A, Eastwood E, Ibrahim AH, Wu N, Grunblatt E, Basom R, Liggitt D, Eaton KD, Martins R, Poirier JT, Rudin CM, Milletti F, Cheng WY, Mack F, MacPherson D. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Science Signaling. 12. PMID 30723171 DOI: 10.1126/Scisignal.Aau2922 |
0.681 |
|
| 2019 |
Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, ... ... Rudin CM, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications. 10: 278. PMID 30655535 DOI: 10.1038/S41467-018-08133-6 |
0.568 |
|
| 2019 |
Lai WV, Rizvi H, Egger JV, Plodkowski AJ, Ginsberg MS, Kris MG, Beras A, Rekhtman N, Poirier JT, Hellmann MD, Rudin CM. Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer. Journal of Clinical Oncology. 37: 8556-8556. DOI: 10.1200/Jco.2019.37.15_Suppl.8556 |
0.587 |
|
| 2019 |
Fernandez L, Poirier J, Rodriguez A, Hulling M, Richardson R, Sutton R, Jiles R, Schonhoft J, Lee J, Ebrahim N, Carbone E, Barnett E, Landers M, Wang Y, Dittamore R, ... Rudin C, et al. Abstract 1348: Characterization of SLFN11 protein expression in circulating tumor cells (CTCs) of patients with metastatic castration resistant prostate cancer (mCRPC) prior to platinum based chemotherapy Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1348 |
0.632 |
|
| 2019 |
Mukherjee S, Srinivasan P, Bandlamudi C, Hellmann MD, Ravichandran V, Selvan ME, Kemel Y, Mandelker D, Zauderer M, Walsh M, Zehir A, Carlo MI, Cadoo K, Lipkin SM, Ladanyi M, ... ... Rudin C, et al. Abstract 1572: Inherited truncatingRAD52variant discovered using integrated germline- somatic analysis predicts clinical outcome in patients with lung cancers Cancer Research. 79: 1572-1572. DOI: 10.1158/1538-7445.Am2019-1572 |
0.459 |
|
| 2019 |
Offin M, Vojnic M, Liu Z, Lui A, Siau E, Gladstone E, Mattar M, Khodos I, Drilon A, Boire A, Rudin C, De Stanchina E, Ladanyi M, Somwar R. LPTO-04. GENERATION AND CHARACTERIZATION OF PATIENT-DERIVED PRECLINICAL MODELS FROM TUMOR CELLS ISOLATED FROM CEREBROSPINAL FLUID Neuro-Oncology Advances. 1: i7-i7. DOI: 10.1093/noajnl/vdz014.027 |
0.349 |
|
| 2019 |
Offin M, Pak T, Mondaca S, Montecalvo J, Rekhtman N, Halpenny D, Wu S, Kris M, Paik P, Riely G, Rudin C, Hyman D, Hellmann M, Drilon A, Land J, et al. P1.04-39 Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers Journal of Thoracic Oncology. 14: S455. DOI: 10.1016/J.Jtho.2019.08.942 |
0.397 |
|
| 2019 |
Tu H, Xu C, Tong-Li C, Offin M, Razavi P, Schapira E, Namakydoust A, Lee A, Pavlakis N, Clarke S, Diakos C, Chan D, Myers M, Makhnin A, Jain H, ... ... Rudin C, et al. P1.01-122 A Clinical Utility Study of Plasma DNA Next Generation Sequencing Guided Treatment of Uncommon Drivers in Advanced Non-Small-Cell Lung Cancers Journal of Thoracic Oncology. 14: S410. DOI: 10.1016/J.Jtho.2019.08.837 |
0.406 |
|
| 2019 |
Lok B, Laird J, Carney B, Kossatz S, De Stanchina E, Reiner T, Poirier J, Rudin C. P1.12-15 PET Imaging of [18F]PARP Inhibitor as a Pharmacodynamic Biomarker of Talazoparib in Small Cell Lung Cancer PDXs Journal of Thoracic Oncology. 14: S539-S540. DOI: 10.1016/J.Jtho.2019.08.1128 |
0.642 |
|
| 2019 |
Yu H, Lang J, Kern J, Pickard SL, Rudin C, Rivard C, Hirsch FR. P1.12-05 Microenvironment Characterization of Small Cell Lung Cancer Xenografts Implanted in Hematopoietic Humanized Mice Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1118 |
0.409 |
|
| 2018 |
Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, ... Rudin CM, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science (New York, N.Y.). 362: 1416-1422. PMID 30573629 DOI: 10.1126/Science.Aas9090 |
0.645 |
|
| 2018 |
Kumar D, Lisok A, Dahmane E, McCoy MD, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, et al. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. The Journal of Clinical Investigation. PMID 30457978 DOI: 10.1172/Jci122216 |
0.527 |
|
| 2018 |
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, ... ... Rudin CM, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018779777. PMID 29989854 DOI: 10.1200/Jco.2018.77.9777 |
0.325 |
|
| 2018 |
Laird JH, Lok BH, Ma J, Bell A, de Stanchina E, Poirier JT, Rudin CM. Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29945991 DOI: 10.1158/1078-0432.Ccr-18-0401 |
0.667 |
|
| 2018 |
Rudin CM. Looking ahead to new therapies in small cell lung cancer. Clinical Advances in Hematology & Oncology : H&O. 16: 269-272. PMID 29742081 |
0.341 |
|
| 2018 |
Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, ... ... Rudin CM, et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. PMID 29657128 DOI: 10.1016/J.Ccell.2018.03.018 |
0.325 |
|
| 2018 |
Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, ... ... Rudin CM, et al. Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer Discovery. PMID 29610121 DOI: 10.1158/2159-8290.Cd-17-1004 |
0.315 |
|
| 2018 |
Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, Weber WA, Rudin CM, Poirier JT, Reiner T. Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nature Communications. 9: 176. PMID 29330466 DOI: 10.1038/S41467-017-02096-W |
0.596 |
|
| 2018 |
Sabari JK, Julian RA, Ni A, Halpenny D, Hellmann MD, Drilon AE, Li BT, Poirier JT, Rudin CM, Rekhtman N. Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden. Journal of Clinical Oncology. 36: e20568-e20568. DOI: 10.1200/Jco.2018.36.15_Suppl.E20568 |
0.579 |
|
| 2018 |
Paik PK, Qeriqi B, Ahn LSH, Ginsberg MS, Tandon N, McFarland D, Doyle LA, de Stanchina E, Rudin CM. Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228. Journal of Clinical Oncology. 36: 9098-9098. DOI: 10.1200/JCO.2018.36.15_suppl.9098 |
0.35 |
|
| 2018 |
Offin MD, Rizvi H, Tenet M, Ni A, Sanchez Vega F, Kris MG, Rudin CM, Riely GJ, Yu HA, Hellmann MD. Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers. Journal of Clinical Oncology. 36: 9042-9042. DOI: 10.1200/jco.2018.36.15_suppl.9042 |
0.301 |
|
| 2018 |
Sabari JK, Offin MD, Wu SL, Ni A, Halpenny D, Montecalvo J, Liu D, Pak TK, Arbour KC, Lai WV, Hellmann MD, Riely GJ, Kris MG, Rudin CM, Rekhtman N, et al. RET-rearranged lung cancers: Immunophenotype and response to immunotherapy. Journal of Clinical Oncology. 36: 9034-9034. DOI: 10.1200/JCO.2018.36.15_SUPPL.9034 |
0.307 |
|
| 2018 |
Vojnic M, Kurzatkowski C, Kubota D, Suzawa K, Liu Z, Mattar M, Khodos I, Poirier JT, de Stanchina E, Rudin CM, Riely GJ, Yu HA, Arcila ME, Ladanyi M, Somwar R. Acquired BRAF fusions as a mechanism of resistance to EGFR therapy. Journal of Clinical Oncology. 36: 12122-12122. DOI: 10.1200/Jco.2018.36.15_Suppl.12122 |
0.595 |
|
| 2018 |
Wang H, Cades J, Yochum Z, Nugent K, Rudin C, Burns T, Tran P. Abstract B47: Modeling epithelial plasticity-induced erlotinib resistance in non-small cell lung cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Mousemodels17-B47 |
0.439 |
|
| 2018 |
Carbone DP, Morgensztern D, Le Moulec S, Santana-Davila R, Ready N, Hann CL, Glisson BS, Dowlati A, Rudin CM, Lally S, Yalamanchili S, Wolf J, Govindan R, Besse B. Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study. Journal of Clinical Oncology. 36: 8507-8507. DOI: 10.1055/S-0039-1678065 |
0.431 |
|
| 2018 |
Li B, Offin M, Hembrough T, Cecchi F, Shen R, Olah Z, Panora E, Myers M, Brzostowski E, Buonocore D, Ginsberg M, Rudin C, Kris M, Weitsman G, Barber P, et al. P1.13-43 Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial Journal of Thoracic Oncology. 13: S599. DOI: 10.1016/J.Jtho.2018.08.900 |
0.378 |
|
| 2018 |
Paik P, Kim R, Ahn L, Plodkowski A, Ng K, Mcfarland D, Iqbal A, Eng J, Rudin C. P1.01-76 A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers Journal of Thoracic Oncology. 13: S492. DOI: 10.1016/J.Jtho.2018.08.632 |
0.395 |
|
| 2018 |
Offin M, Dienstag J, Wilkins O, Sabari J, Ni A, Feldman D, Van Voorthuysen M, Suzawa K, Yu H, Riely G, Arcila M, Ladanyi M, Kris M, Rudin C, Somwar R, et al. P1.01-74 MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition Journal of Thoracic Oncology. 13: S491. DOI: 10.1016/J.Jtho.2018.08.630 |
0.394 |
|
| 2018 |
Lok B, Laird J, Ma J, De Stanchina E, Poirier J, Rudin C. MA22.01 PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency Journal of Thoracic Oncology. 13: S433. DOI: 10.1016/J.Jtho.2018.08.501 |
0.684 |
|
| 2018 |
Offin M, Tenet M, Shen R, Rekhtman N, Rizvi H, Hellmann M, Arcila M, Ladanyi M, Rudin C, Kris M, Yu H. MA16.04 Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations Journal of Thoracic Oncology. 13: S412. DOI: 10.1016/J.Jtho.2018.08.450 |
0.387 |
|
| 2018 |
Owonikoko T, Dahlberg S, Sica G, Poirier J, Byers L, Rudin C, Wistuba I, Ramalingam S. P3.12-06 SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study Journal of Thoracic Oncology. 13: S972. DOI: 10.1016/J.Jtho.2018.08.1829 |
0.674 |
|
| 2018 |
Paik P, Ahn L, Ginsberg M, Mcfarland D, Doyle L, Rudin C. P2.13-44 Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228 Journal of Thoracic Oncology. 13: S816. DOI: 10.1016/J.Jtho.2018.08.1439 |
0.448 |
|
| 2018 |
Laird J, Lok B, Ma J, Bell A, De Stanchina E, Poirier J, Rudin C. PARP trapping by Talazoparib is a Potent Mechanism of Radiosensitization in Small Cell Lung Cancer Cell Lines and Patient-Derived Xenografts International Journal of Radiation Oncology*Biology*Physics. 102: e184-e185. DOI: 10.1016/J.Ijrobp.2018.07.676 |
0.661 |
|
| 2017 |
Majem M, Rudin CM. Small-cell lung cancer in the era of immunotherapy. Translational Lung Cancer Research. 6: S67-S70. PMID 29299415 DOI: 10.21037/tlcr.2017.10.06 |
0.371 |
|
| 2017 |
Chang MT, Penson AV, Desai NB, Socci ND, Shen R, Seshan V, Kundra R, Abeshouse AA, Viale A, Cha EK, Hao X, Reuter V, Rudin CM, Bochner BH, Rosenberg JE, et al. Small cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29180607 DOI: 10.1158/1078-0432.CCR-17-2655 |
0.376 |
|
| 2017 |
Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, ... ... Rudin CM, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nature Medicine. PMID 28967920 DOI: 10.1038/Nm.4407 |
0.73 |
|
| 2017 |
Yochum ZA, Cades J, Mazzacurati L, Neumann NM, Khetarpal SK, Chatterjee S, Wang H, Attar MA, Huang EH, Chatley SN, Nugent K, Somasundaram A, Engh J, Ewald AJ, Cho YJ, ... Rudin CM, et al. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-driven Lung Cancer. Molecular Cancer Research : McR. PMID 28851812 DOI: 10.1158/1541-7786.Mcr-17-0298 |
0.39 |
|
| 2017 |
Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. The Journal of Clinical Investigation. PMID 28650343 DOI: 10.1172/Jci93472 |
0.56 |
|
| 2017 |
Soo RA, Stone EC, Cummings KM, Jett JR, Field JK, Groen HJ, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, ... ... Rudin CM, et al. Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28579481 DOI: 10.1016/J.Jtho.2017.05.019 |
0.334 |
|
| 2017 |
Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nature Reviews. Clinical Oncology. PMID 28534531 DOI: 10.1038/Nrclinonc.2017.71 |
0.627 |
|
| 2017 |
Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K, Bheddah S, Sandoval J, Cunanan KM, Johansen EB, Allaj V, Sisodiya V, ... ... Rudin CM, et al. Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Research. PMID 28487384 DOI: 10.1158/0008-5472.Can-17-0299 |
0.628 |
|
| 2017 |
Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. Molecular Cancer Therapeutics. PMID 28468780 DOI: 10.1158/1535-7163.Mct-16-0821 |
0.591 |
|
| 2017 |
Offin M, Chabon JJ, Razavi P, Isbell JM, Rudin CM, Diehn M, Li BT. Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Journal of Oncology. 2017: 4517834. PMID 28392802 DOI: 10.1155/2017/4517834 |
0.322 |
|
| 2017 |
Gardner EE, Poirier JT, Rudin CM. Histone Code Aberrancies in Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 12: 599-601. PMID 28343540 DOI: 10.1016/J.Jtho.2017.02.008 |
0.62 |
|
| 2017 |
Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, ... ... Rudin CM, et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 31: 286-299. PMID 28196596 DOI: 10.1016/J.Ccell.2017.01.006 |
0.67 |
|
| 2017 |
Chaft JE, Dahlberg SE, Gerber DE, Oxnard GR, Malik SM, Simone CB, Edelman MJ, Heymach J, Rudin CM, Ramalingam SS. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform. Journal of Clinical Oncology. 35: TPS8575-TPS8575. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS8575 |
0.318 |
|
| 2017 |
Lai WV, Lebas L, Milia J, Barnes TA, Gautschi O, Peters S, Ferrara R, Ni A, Sabari JK, Clarke SJ, Pavlakis N, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, et al. Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study. Journal of Clinical Oncology. 35: 9071-9071. DOI: 10.1200/JCO.2017.35.15_SUPPL.9071 |
0.327 |
|
| 2017 |
Pandha H, Harrington K, Ralph C, Melcher A, Gupta S, Akerley W, Sandborn RE, Rudin C, Rosenberg J, Kaufman D, Schmidt E, Grose M, Shafren DR. Abstract CT115: Phase 1bKEYNOTE 200 (STORM study):A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct115 |
0.38 |
|
| 2017 |
Zhang C, Graf R, Jendrisak A, Anderson AK, Ontiveros P, Orr S, Chiang A, Spigel D, Rudin C, Holmgren E, Dupont J, Argast G, Faoro L, Zhou L, Lewicki J, et al. Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome Cancer Research. 77: 1727-1727. DOI: 10.1158/1538-7445.Am2017-1727 |
0.422 |
|
| 2017 |
Rudin C, Shen L, Pietanza M. KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC) Annals of Oncology. 28: v541. DOI: 10.1093/ANNONC/MDX386.008 |
0.307 |
|
| 2017 |
Daniel D, Rudin C, Hart L, Spigel D, Edelman M, Goldschmidt J, Bordoni R, Glisson B, Burns T, Dowlati A, Dy G, Beck T, Jotte R, Liu S, Kapoun A, et al. Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC) Annals of Oncology. 28: v540. DOI: 10.1093/ANNONC/MDX386.004 |
0.306 |
|
| 2017 |
Paik P, Srikakulum A, Ahn L, Plodkowski A, Ng K, Mcfarland D, Fiore J, Iqbal A, Eng J, Kris M, Rudin C. P1.03-028 A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Untreated Stage IV Squamous Cell Lung Cancers Journal of Thoracic Oncology. 12: S1961-S1962. DOI: 10.1016/J.Jtho.2017.09.832 |
0.397 |
|
| 2017 |
Velcheti V, Schwartz S, Cecchi F, Tian Y, Sellappan S, Rudin C, Poirier J, Hembrough T. P1.02-001 SLFN11 Expression in Early Stage Non-Small Cell Lung Cancer Predicts Benefit from Adjuvant Chemotherapy with Taxane and Platinum Journal of Thoracic Oncology. 12: S1924-S1925. DOI: 10.1016/J.Jtho.2017.09.733 |
0.659 |
|
| 2017 |
Li B, Shen R, Buonocore D, Olah Z, Ni A, Ginsberg M, Ulaner G, Weber W, Tsui D, Offin M, Won H, Ladanyi M, Riely G, Solit D, Hyman D, ... Rudin C, et al. OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers Journal of Thoracic Oncology. 12: S1783. DOI: 10.1016/J.Jtho.2017.09.410 |
0.393 |
|
| 2017 |
Sabari J, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos C, Offin M, Datta S, Tandon N, Duboff M, Simpronio J, Martinez A, Isbell J, Rusch V, ... ... Rudin C, et al. OA 10.03 Liquid Biopsy in the Lung Cancer Clinic: A Prospective Study of Plasma DNA next Generation Sequencing to Guide Matched Therapy Journal of Thoracic Oncology. 12: S1772. DOI: 10.1016/J.Jtho.2017.09.384 |
0.358 |
|
| 2017 |
Owonikoko T, Dahlberg S, Poirier J, Sica G, Rudin C, Ramalingam S. OA 08.06 Exploratory Analysis for Predictors of Benefit of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study Journal of Thoracic Oncology. 12: S1766-S1767. DOI: 10.1016/J.Jtho.2017.09.373 |
0.676 |
|
| 2017 |
Lok B, Laird J, Carney B, Kossatz S, Donabedian P, Shah N, Sadique A, De StanChina E, Reiner T, Poirier J, Rudin C. P3.15-008 [F18]PARPi PET as an In Vivo Pharmacodynamic Biomarker of PARP Inhibitor Therapy in Patient-Derived Xenografts of Small Cell Lung Cancer Journal of Thoracic Oncology. 12: S2340-S2341. DOI: 10.1016/J.Jtho.2017.09.1798 |
0.657 |
|
| 2017 |
Byers LA, Krug L, Waqar S, Dowlati A, Hann C, Chiappori A, Owonikoko T, Woo K, Bensman Y, Hurtado B, Cardnell R, Diao L, Fan Y, Fujimoto J, Rodriguez-Canales J, ... ... Rudin C, et al. MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial Journal of Thoracic Oncology. 12: S406-S407. DOI: 10.1016/J.Jtho.2016.11.466 |
0.41 |
|
| 2017 |
Drilon A, Somwar R, Smith R, Delasos L, Albano M, Van Voorthuyson M, Wang L, Rekhtman N, Ni A, Plodkowski A, Ginsberg M, Riely G, Rudin C, Ladanyi M, Kris M. OA11.05 A Phase 2 Study of Cabozantinib for Patients with Advanced RET-Rearranged Lung Cancers Journal of Thoracic Oncology. 12: S286-S287. DOI: 10.1016/J.Jtho.2016.11.291 |
0.405 |
|
| 2017 |
Spigel D, Pietanza MC, Bauer T, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson M, Burris H, Robert F, Han T, Bheddah S, Theiss N, Watson S, Mathur D, ... ... Rudin C, et al. OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC) Journal of Thoracic Oncology. 12: S260-S261. DOI: 10.1016/J.Jtho.2016.11.252 |
0.421 |
|
| 2017 |
Laird J, Lok B, Carney B, Kossatz S, Ma J, Bell A, Shah N, Sadique A, De Stanchina E, Reiner T, Poirier J, Rudin C. [ 18 F]PARPi PET as a Marker of Intratumoral Talazoparib Level in Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 99: S54. DOI: 10.1016/J.Ijrobp.2017.06.136 |
0.605 |
|
| 2016 |
Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer (Amsterdam, Netherlands). 102: 21-27. PMID 27987583 DOI: 10.1016/j.lungcan.2016.10.004 |
0.337 |
|
| 2016 |
Rudin CM, Poirier JT. Small-cell lung cancer in 2016: Shining light on novel targets and therapies. Nature Reviews. Clinical Oncology. PMID 27958293 DOI: 10.1038/Nrclinonc.2016.203 |
0.643 |
|
| 2016 |
Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. The Lancet. Oncology. PMID 27932068 DOI: 10.1016/S1470-2045(16)30565-4 |
0.346 |
|
| 2016 |
Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. The Lancet. Oncology. PMID 27825636 DOI: 10.1016/S1470-2045(16)30562-9 |
0.357 |
|
| 2016 |
Lok BH, Feng Y, Gardner EE, Yu GK, Ru YK, Riaz N, deStanchina E, Powell SN, Shen YJ, Poirier JT, Rudin CM. SLFN11 Is Necessary for Single Agent Sensitivity to Talazoparib, a Potent PARP Inhibitor, But Not for Radiosensitization in Small Cell Lung Cancer (SCLC) Cell Lines and Patient-Derived Xenografts (PDX). International Journal of Radiation Oncology, Biology, Physics. 96: S75. PMID 27676009 DOI: 10.1016/J.Ijrobp.2016.06.191 |
0.662 |
|
| 2016 |
Schneeberger VE, Allaj V, Gardner EE, Poirier JT, Rudin CM. Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis. Plos One. 11: e0160587. PMID 27611664 DOI: 10.1371/Journal.Pone.0160587 |
0.62 |
|
| 2016 |
Pietanza MC, Litvak AM, Varghese AM, Krug LM, Fleisher M, Teitcher JB, Holodny AI, Sima CS, Woo KM, Ng KK, Won HH, Berger MF, Kris MG, Rudin CM. A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 99: 23-30. PMID 27565909 DOI: 10.1016/j.lungcan.2016.04.014 |
0.366 |
|
| 2016 |
Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27440269 DOI: 10.1158/1078-0432.Ccr-16-1040 |
0.663 |
|
| 2016 |
Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, Adler K, Baut E, Scaltriti M, Jena PV, Gardner EE, Poirier JT, Rudin CM, Baselga J, Haimovitz-Friedman A, et al. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Science Translational Medicine. 8: 345ra87. PMID 27358497 DOI: 10.1126/Scitranslmed.Aaf7374 |
0.562 |
|
| 2016 |
Manchado E, Weissmueller S, Morris JP, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. PMID 27338794 DOI: 10.1038/Nature18600 |
0.673 |
|
| 2016 |
Paik PK, Rudin CM. Missing the mark in FGFR1-amplified squamous cell cancer of the lung. Cancer. PMID 27315203 DOI: 10.1002/cncr.30131 |
0.364 |
|
| 2016 |
Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, ... ... Rudin CM, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of Clinical Investigation. PMID 27294525 DOI: 10.1172/Jci81603 |
0.593 |
|
| 2016 |
Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. PMID 27163943 DOI: 10.1002/cncr.30062 |
0.394 |
|
| 2016 |
Rekhtman N, Pietanza MC, Hellmann M, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon A, Socci N, Poirier JT, Shen R, ... ... Rudin CM, et al. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26960398 DOI: 10.1158/1078-0432.Ccr-15-2946 |
0.592 |
|
| 2016 |
Bunn PA, Minna J, Augustyn A, Gazdar A, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier J, ... ... Rudin CM, et al. Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26829312 DOI: 10.1016/J.Jtho.2016.01.012 |
0.628 |
|
| 2016 |
Somwar R, Smith R, Hayashi T, Ishizawa K, Snyder Charen A, Khodos I, Mattar M, He J, Balasubramanian S, Stephens P, Lipson D, de Stanchina E, Davare M, Miller VA, Riely GJ, ... Rudin CM, et al. MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers. Journal of Clinical Oncology. 34: 9068-9068. DOI: 10.1200/Jco.2016.34.15_Suppl.9068 |
0.317 |
|
| 2016 |
Chiang AC, Rudin CM, Spira AI, Jotte RM, Gadgeel SM, Mita AC, Hart LL, Gluck WL, Liu SV, Kapoun AM, Xu L, Hill D, Zhou L, Dupont J, Spigel DR. Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal of Clinical Oncology. 34: 8564-8564. DOI: 10.1200/JCO.2016.34.15_SUPPL.8564 |
0.308 |
|
| 2016 |
Rusch VW, Tan KS, Ghanie A, Arcila ME, Travis WD, Jones DR, Park BJ, Huang J, Rudin CM, Hyman DM, Solit DB, Berger MF, Baselga J, Ladanyi M, Riely GJ. Next generation sequencing (NGS) in resectable non-small cell lung cancer (NSCLC): Therapeutic implications. Journal of Clinical Oncology. 34: 8541-8541. DOI: 10.1200/JCO.2016.34.15_suppl.8541 |
0.343 |
|
| 2016 |
Pietanza MC, Krug LM, Waqar SN, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo K, Bensman Y, Hurtado B, Fujimoto J, Wistuba II, Travis WD, Chen AP, Heymach J, ... ... Rudin CM, et al. A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs). Journal of Clinical Oncology. 34: 8512-8512. DOI: 10.1200/JCO.2016.34.15_SUPPL.8512 |
0.311 |
|
| 2016 |
Chu Q, Markman B, Leighl N, Krug L, Rudin C, Lathers D, Basciano P, Fracasso P, Kollia G, Phillips P, Kolaitis G, Williams D, Jackson J, Ready N. A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy Annals of Oncology. 27: vi494. DOI: 10.1093/Annonc/Mdw389.05 |
0.405 |
|
| 2016 |
Janku F, Murthy R, Wang-Gillam A, Shepard D, Helgason T, Henry T, Rudin C, Huang S, Sakamuri D, Solomon S, Collins A, Kreider B, Miller M, Saha S, Tung D, et al. Phase I clinical study of intratumoral injection of oncolytic Clostridium novyi-NT spores in patients with advanced cancers European Journal of Cancer. 69: S94. DOI: 10.1016/S0959-8049(16)32878-7 |
0.328 |
|
| 2015 |
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, ... ... Rudin CM, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Science Translational Medicine. 7: 302ra136. PMID 26311731 DOI: 10.1126/Scitranslmed.Aac9459 |
0.611 |
|
| 2015 |
Miles LA, Brennen WN, Rudin CM, Poirier JT. Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy. Plos One. 10: e0136480. PMID 26287921 DOI: 10.1371/Journal.Pone.0136480 |
0.564 |
|
| 2015 |
Miles LA, Brennen WN, Rudin CM, Poirier JT. Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy. Plos One. 10: e0129103. PMID 26069962 DOI: 10.1371/journal.pone.0129103 |
0.565 |
|
| 2015 |
Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2244-55. PMID 25979931 DOI: 10.1158/1078-0432.CCR-14-2958 |
0.314 |
|
| 2015 |
Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, ... ... Rudin CM, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications. 6: 6377. PMID 25758528 DOI: 10.1038/Ncomms7377 |
0.648 |
|
| 2015 |
Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. PMID 25746006 DOI: 10.1038/Onc.2015.38 |
0.623 |
|
| 2015 |
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: S1-63. PMID 25535693 DOI: 10.1097/Jto.0000000000000405 |
0.368 |
|
| 2015 |
Vendetti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, Poirier JT, Rudin CM. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 6: 56-70. PMID 25474141 DOI: 10.18632/Oncotarget.2695 |
0.628 |
|
| 2015 |
Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 121: 664-72. PMID 25336398 DOI: 10.1002/cncr.29098 |
0.359 |
|
| 2015 |
Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatric Blood & Cancer. 62: 743-50. PMID 25307519 DOI: 10.1002/Pbc.25269 |
0.512 |
|
| 2015 |
Pietanza MC, Won HH, Rekhtman N, Wang L, Travis WD, Krug LM, Varghese AM, Paik PK, Riely GJ, Zakowski MF, Ladanyi M, Berger MF, Kris MG, Rudin CM. Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS). Journal of Clinical Oncology. 33: 7518-7518. DOI: 10.1200/JCO.2015.33.15_SUPPL.7518 |
0.334 |
|
| 2015 |
Schneeberger V, Poirier J, Rudin C. Abstract LB-286: The patient-derived xenograft mouse model dilemma; a new solution for an old problem Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-286 |
0.658 |
|
| 2015 |
Janku F, Gounder M, Murthy R, Rudin C, Helgason T, Hong D, Benjamin R, Meyer L, Zinner R, Meric-Bernstam F, Masters T. Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer Annals of Oncology. 26: ii16. DOI: 10.1093/Annonc/Mdv090.9 |
0.309 |
|
| 2015 |
Pietanza M, Spigel D, Bauer T, Ready N, Glisson B, Morgensztern D, Robert F, Salgia R, Kochendorfer M, Patel M, Strickland D, Govindan R, Burris H, Rudin C, Dylla S. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC) European Journal of Cancer. 51: S712. DOI: 10.1016/S0959-8049(16)31931-1 |
0.305 |
|
| 2014 |
Drilon A, Sugita H, Sima CS, Zauderer M, Rudin CM, Kris MG, Rusch VW, Azzoli CG. A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1272-7. PMID 25122424 DOI: 10.1097/JTO.0000000000000256 |
0.317 |
|
| 2014 |
Rudin CM, Drilon A, Poirier JT. RET mutations in neuroendocrine tumors: including small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1240-2. PMID 25122419 DOI: 10.1097/Jto.0000000000000301 |
0.676 |
|
| 2014 |
Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA, et al. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Medicine. 3: 1322-35. PMID 24989836 DOI: 10.1002/Cam4.289 |
0.302 |
|
| 2014 |
Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge DR, Bauman JE, Hausman D, Walker L, Nemunaitis J, Rudin CM, Halmos B, Bowles DW. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1031-5. PMID 24926548 DOI: 10.1097/JTO.0000000000000183 |
0.307 |
|
| 2014 |
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, ... ... Rudin C, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 311: 1998-2006. PMID 24846037 DOI: 10.1001/Jama.2014.3741 |
0.42 |
|
| 2014 |
Dogan I, Kawabata S, Bergbower E, Gills JJ, Ekmekci A, Wilson W, Rudin CM, Dennis PA. SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer (Amsterdam, Netherlands). 85: 1-6. PMID 24746758 DOI: 10.1016/j.lungcan.2014.03.021 |
0.316 |
|
| 2014 |
Gardner EE, Connis N, Poirier JT, Cope L, Dobromilskaya I, Gallia GL, Rudin CM, Hann CL. Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Research. 74: 2846-56. PMID 24614082 DOI: 10.1158/0008-5472.Can-13-3460 |
0.652 |
|
| 2014 |
Rudin CM, Poirier JT. MYC, MAX, and small cell lung cancer. Cancer Discovery. 4: 273-4. PMID 24596200 DOI: 10.1158/2159-8290.Cd-14-0069 |
0.659 |
|
| 2014 |
Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: E748-57. PMID 24550319 DOI: 10.1073/Pnas.1320956111 |
0.321 |
|
| 2014 |
Pietanza MC, Krug LM, Varghese AM, Fleisher M, Teitcher JB, Holodny A, Sima CS, Litvak AM, Ng KK, Patel PR, Ibrahim F, Haughney-Siller A, Dulko D, Monger G, Albano M, ... ... Rudin CM, et al. Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology. 32: 7602-7602. DOI: 10.1200/JCO.2014.32.15_SUPPL.7602 |
0.329 |
|
| 2014 |
Chatley SN, Cades J, Neumann N, Mazzacurati L, Yochum Z, Nugent K, Cho Y, Ewald A, Rudin C, Tran P, Burns TF. Abstract 4771: Identification of inhibitors of TWIST1 as a treatment for lung cancer Cancer Research. 74: 4771-4771. DOI: 10.1158/1538-7445.Am2014-4771 |
0.507 |
|
| 2014 |
Rudin CM. Abstract IA03: Genomic and epigenomic targets in small cell lung cancer. Clinical Cancer Research. 20: IA03-IA03. DOI: 10.1158/1078-0432.14AACRIASLC-IA03 |
0.341 |
|
| 2014 |
Bai R, Staedtke V, Rudin C, Bunz F, Riggins G. ET-04 * MEBENDAZOLE IS EFFICACIOUS IN DIVERSE MEDULLOBLASTOMA TUMOR MODELS AND INHIBITS TUMOR ANGIOGENESIS Neuro-Oncology. 16: v79-v79. DOI: 10.1093/Neuonc/Nou255.4 |
0.355 |
|
| 2014 |
Rudin C, Connis N, Hann C, Poirier J. Epigenetic Analysis of Small Cell Lung Cancer Defines Distinct Disease Subsets International Journal of Radiation Oncology*Biology*Physics. 90: S65-S66. DOI: 10.1016/J.Ijrobp.2014.08.289 |
0.645 |
|
| 2013 |
Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, ... ... Rudin CM, et al. The twist box domain is required for Twist1-induced prostate cancer metastasis. Molecular Cancer Research : McR. 11: 1387-400. PMID 23982216 DOI: 10.1158/1541-7786.Mcr-13-0218-T |
0.327 |
|
| 2013 |
Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. Journal of the National Cancer Institute. 105: 1059-65. PMID 23739064 DOI: 10.1093/Jnci/Djt130 |
0.631 |
|
| 2013 |
Juergens RA, Rudin CM. Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. PMID 23714528 DOI: 10.1200/EdBook_AM.2013.33.e295 |
0.317 |
|
| 2013 |
Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 619-23. PMID 23546045 DOI: 10.1097/Jto.0B013E31828C3950 |
0.389 |
|
| 2013 |
Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: e41-2. PMID 23524406 DOI: 10.1097/JTO.0b013e31828bb1b3 |
0.36 |
|
| 2013 |
Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2584-91. PMID 23515407 DOI: 10.1158/1078-0432.Ccr-12-3173 |
0.338 |
|
| 2013 |
Zinn RL, Gardner EE, Dobromilskaya I, Murphy S, Marchionni L, Hann CL, Rudin CM. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Molecular Cancer. 12: 16. PMID 23452820 DOI: 10.1186/1476-4598-12-16 |
0.409 |
|
| 2013 |
Kamat CD, Shmueli RB, Connis N, Rudin CM, Green JJ, Hann CL. Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo. Molecular Cancer Therapeutics. 12: 405-15. PMID 23364678 DOI: 10.1158/1535-7163.MCT-12-0956 |
0.313 |
|
| 2013 |
Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SN, Aziz K, Cho YJ, Tran PT, Rudin CM. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. Molecular Cancer Research : McR. 11: 329-38. PMID 23364532 DOI: 10.1158/1541-7786.MCR-12-0456 |
0.34 |
|
| 2013 |
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, ... ... Rudin CM, et al. Small cell lung cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 78-98. PMID 23307984 DOI: 10.6004/jnccn.2013.0011 |
0.305 |
|
| 2013 |
Zeng J, Aziz K, Chettiar ST, Aftab BT, Armour M, Gajula R, Gandhi N, Salih T, Herman JM, Wong J, Rudin CM, Tran PT, Hales RK. Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. International Journal of Radiation Oncology, Biology, Physics. 86: 143-9. PMID 23182391 DOI: 10.1016/j.ijrobp.2012.10.014 |
0.377 |
|
| 2013 |
Gajula R, Chettiar S, Williams R, Thiyagarajan S, Aziz K, Gandhi N, Wild A, Salih T, Kato Y, Cades J, Fertig E, Chung C, Herman J, Hales R, Rudin C, et al. Abstract B45: The Twist box domain is required for Twist1-induced metastasis of prostate cancer cells Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-B45 |
0.45 |
|
| 2013 |
Wrangle J, Wang W, Koch A, Easwaran H, Mohammad H, Parsana P, Vendetti F, Rodgers K, Pan X, Harbom K, Zahnow C, Taube J, Brahmer J, Jones P, Topalian S, ... Rudin C, et al. Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy. Cancer Research. 73: 4619-4619. DOI: 10.1158/1538-7445.Am2013-4619 |
0.455 |
|
| 2012 |
Poirier JT, Reddy PS, Idamakanti N, Li SS, Stump KL, Burroughs KD, Hallenbeck PL, Rudin CM. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001. The Journal of General Virology. 93: 2606-13. PMID 22971818 DOI: 10.1099/Vir.0.046011-0 |
0.574 |
|
| 2012 |
Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genetics. 44: 1111-6. PMID 22941189 DOI: 10.1038/Ng.2405 |
0.65 |
|
| 2012 |
Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH, ... ... Rudin CM, et al. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. Plos Genetics. 8: e1002650. PMID 22654667 DOI: 10.1371/Journal.Pgen.1002650 |
0.351 |
|
| 2012 |
Forde PM, Rudin CM. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opinion On Pharmacotherapy. 13: 1195-201. PMID 22594847 DOI: 10.1517/14656566.2012.688029 |
0.389 |
|
| 2012 |
Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3163-9. PMID 22496272 DOI: 10.1158/1078-0432.CCR-11-3090 |
0.334 |
|
| 2012 |
Pietanza MC, Rudin CM. Novel therapeutic approaches for small cell lung cancer: the future has arrived. Current Problems in Cancer. 36: 156-73. PMID 22495056 DOI: 10.1016/j.currproblcancer.2012.03.005 |
0.359 |
|
| 2012 |
Paller C, Wissing M, Kim E, Hammers H, Rudin C, Carducci M, Kachhap S. Abstract 2049: Preclinical profile of AMG900 in combination with HDACIs in prostate cancer Cancer Research. 72: 2049-2049. DOI: 10.1158/1538-7445.Am2012-2049 |
0.399 |
|
| 2012 |
Rudin C, Durinck S, Stawiski E, Poirier J, Modrusan Z, Bergbower E, Illei P, Varella-Garcia M, Minna J, Seshagiri S. 552 Comprehensive Genomic Profiling of Small Cell Lung Cancer Reveals SOX2 Amplification and MYCL1 Rearrangements European Journal of Cancer. 48: 170. DOI: 10.1016/S0959-8049(12)72349-3 |
0.644 |
|
| 2012 |
Tran P, Hales R, Zeng J, Aziz K, Armour M, Aftab B, Chettiar S, Gajula R, Salih T, Rudin C, Gandhi N, Wong J. 34 HEDGEHOG PATHWAY INHIBITION AND RADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER Radiotherapy and Oncology. 102: S10. DOI: 10.1016/S0167-8140(12)70021-X |
0.485 |
|
| 2011 |
Burns TF, Dobromilskaya I, Murphy S, Thiyagarajan S, Das S, Tran PT, Rudin CM. Reactivation of oncogene-induced senescence in KRAS mutant non-small cell lung cancer by inhibition of TWIST1. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10591. PMID 28021973 DOI: 10.1200/jco.2011.29.15_suppl.10591 |
0.362 |
|
| 2011 |
Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, ... ... Rudin CM, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discovery. 1: 598-607. PMID 22586682 DOI: 10.1158/2159-8290.Cd-11-0214 |
0.304 |
|
| 2011 |
Osanyingbemi-Obidi J, Dobromilskaya I, Illei PB, Hann CL, Rudin CM. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Molecular Cancer Research : McR. 9: 1746-54. PMID 21994468 DOI: 10.1158/1541-7786.MCR-11-0286 |
0.354 |
|
| 2011 |
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, ... ... Rudin CM, et al. Small cell lung cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 1086-113. PMID 21975911 |
0.366 |
|
| 2011 |
Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1757-60. PMID 21918390 DOI: 10.1097/JTO.0b013e31822e2941 |
0.34 |
|
| 2011 |
Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Research. 71: 6764-72. PMID 21896639 DOI: 10.1158/0008-5472.Can-11-0691 |
0.359 |
|
| 2011 |
Husain H, Rudin CM. ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park, N.Y.). 25: 597-601. PMID 21888258 |
0.379 |
|
| 2011 |
Rudin CM, Poirier JT, Senzer NN, Stephenson J, Loesch D, Burroughs KD, Reddy PS, Hann CL, Hallenbeck PL. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 888-95. PMID 21304001 DOI: 10.1158/1078-0432.Ccr-10-1706 |
0.648 |
|
| 2011 |
Rudin CM, Mauer A, Smakal M, Juergens R, Spelda S, Wertheim M, Coates A, McKeegan E, Ansell P, Zhou X, Qian J, Pradhan R, Dowell B, Krivoshik A, Gordon G. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1075-82. PMID 21300929 DOI: 10.1200/Jco.2010.32.5944 |
0.321 |
|
| 2011 |
Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, ... ... Rudin CM, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 909-16. PMID 21282543 DOI: 10.1200/JCO.2010.31.6208 |
0.309 |
|
| 2011 |
Juergens R, Vendetti F, Wrangle J, Coleman B, Sebree R, Rudek-Renaut M, Belinsky S, Brock M, Herman J, Baylin S, Rudin C. Abstract LB-411: A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-411 |
0.397 |
|
| 2010 |
Rudin CM, Oliveira MR, Garon EB, Bonomi P, Camidge DR, Nolan C, Busman T, Krivoshik A, Humerickhouse R, Gandhi L. A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC). Journal of Clinical Oncology. 28: 7046-7046. DOI: 10.1200/JCO.2010.28.15_SUPPL.7046 |
0.347 |
|
| 2010 |
Lopes EC, Gozman A, Taldone T, Ahn J, Marubayashi S, Rudin C, Levine RL, Nimer S, Chiosis G. Determinants of Apoptotic Sensitivity to HSP90 Inhibition In Acute Myeloid Leukemia Blood. 116: 2159-2159. DOI: 10.1182/Blood.V116.21.2159.2159 |
0.391 |
|
| 2009 |
Brown AB, Rudin C, Rizvi N, Travis W, Takebe N, James LP, Subzwari S, Tyson L, Markus S, Krug LM. Phase I study of obatoclax mesylate (GX15-070MS), a bcl-2 antagonist, plus topotecan in relapsed small cell lung carcinoma and other solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3504. PMID 27961280 DOI: 10.1200/Jco.2009.27.15_Suppl.3504 |
0.392 |
|
| 2009 |
Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, Di Cello F, Kowalski J, Elbahloul O, Segal J, Poirier J, Rudin CM, Dhara S, Belton A, Joseph B, Zucker S, Resar LM. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Molecular Cancer Research : McR. 7: 1803-12. PMID 19903768 DOI: 10.1158/1541-7786.Mcr-08-0336 |
0.653 |
|
| 2009 |
Rudin C, Minna J. Cancer stem cells. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: S1079-81. PMID 19861925 DOI: 10.1097/01.Jto.0000361758.17413.7C |
0.477 |
|
| 2009 |
Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5646-61. PMID 19755392 DOI: 10.1158/1078-0432.Ccr-09-0377 |
0.322 |
|
| 2009 |
Rudin CM, Avila-Tang E, Samet JM. Lung cancer in never smokers: a call to action. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5622-5. PMID 19755390 DOI: 10.1158/1078-0432.Ccr-09-0373 |
0.308 |
|
| 2009 |
Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, Watkins DN. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Research. 69: 3364-73. PMID 19351829 DOI: 10.1158/0008-5472.CAN-08-4210 |
0.353 |
|
| 2009 |
Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 264-70. PMID 19047285 DOI: 10.1200/Jco.2008.17.4656 |
0.341 |
|
| 2009 |
Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R, Den Boer ML. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 113: 2014-21. PMID 18978206 DOI: 10.1182/Blood-2008-05-157842 |
0.645 |
|
| 2009 |
Yauch R, Januario T, Fu L, Holcomb T, Stinson J, Pujara K, Callahan C, Koeppen H, Reddy J, Hoff DV, LoRusso P, Rudin C, Sauvage Fd, Low J. Abstract A44: Predictive biomarkers of efficacy to the hedgehog pathway inhibitor, GDC‐0449, in advanced basal cell carcinoma and medulloblastoma in phase I studies Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A44 |
0.374 |
|
| 2008 |
Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, Rudin CM. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Research. 68: 2321-8. PMID 18381439 DOI: 10.1158/0008-5472.CAN-07-5031 |
0.378 |
|
| 2008 |
Rudin CM, Hann CL, Peacock CD, Watkins DN. Novel systemic therapies for small cell lung cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 6: 315-22. PMID 18377849 DOI: 10.6004/JNCCN.2008.0026 |
0.346 |
|
| 2007 |
Hann CL, Rudin CM. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends in Molecular Medicine. 13: 150-7. PMID 17324626 DOI: 10.1016/j.molmed.2007.02.003 |
0.403 |
|
| 2007 |
Hagan CR, Rudin CM. DNA cleavage and Trp53 differentially affect SINE transcription. Genes, Chromosomes & Cancer. 46: 248-60. PMID 17171681 DOI: 10.1002/Gcc.20406 |
0.702 |
|
| 2007 |
Brace JL, Lester RL, Dickson RC, Rudin CM. SVF1 regulates cell survival by affecting sphingolipid metabolism in Saccharomyces cerevisiae. Genetics. 175: 65-76. PMID 17057230 DOI: 10.1534/genetics.106.064527 |
0.781 |
|
| 2007 |
Eliopoulos H, Oliveira M, Mauer A, Rudin C, Coates A, Zhou X, Xiong H, Hagey A. P2-175: Phase 1/2 trial of ABT-751 in combination with pemetrexed vs pemetrexed alone in subjects with advanced or metastatic non-small-cell lung cancer (NSCLC) Journal of Thoracic Oncology. 2: S639. DOI: 10.1097/01.Jto.0000283833.08160.25 |
0.427 |
|
| 2006 |
Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD, Villano JL, Kozloff M, Wade JL, Sciortino DF, Szeto L, Vokes EE. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 245-51. PMID 17409864 DOI: 10.1016/S1556-0864(15)31575-6 |
0.34 |
|
| 2006 |
Ross HJ, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, McCune DE, Rosenberg AH, Baron AD, Grove LE, Thorn MD, Miller DM, Drachman JG, Rudin CM. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer (Amsterdam, Netherlands). 54: 69-77. PMID 16934909 DOI: 10.1016/j.lungcan.2006.05.020 |
0.309 |
|
| 2005 |
Vanderweele DJ, Rudin CM. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate. Molecular Cancer Research : McR. 3: 635-44. PMID 16317089 DOI: 10.1158/1541-7786.Mcr-05-0063 |
0.648 |
|
| 2005 |
Brace JL, Vanderweele DJ, Rudin CM. Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress in Saccharomyces cerevisiae. Yeast (Chichester, England). 22: 641-52. PMID 16034825 DOI: 10.1002/Yea.1235 |
0.782 |
|
| 2005 |
Brock MV, Hooker CM, Syphard JE, Westra W, Xu L, Alberg AJ, Mason D, Baylin SB, Herman JG, Yung RC, Brahmer J, Rudin CM, Ettinger DS, Yang SC. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. The Journal of Thoracic and Cardiovascular Surgery. 129: 64-72. PMID 15632826 DOI: 10.1016/J.Jtcvs.2004.08.022 |
0.307 |
|
| 2005 |
McDonald M, Rarik M, Rudin C, Wahl R, Vansant J, Leal J, Grove L, Miller D, Ross HJ. Pilot study of SGN-15 immunoconjugate with docetaxel as first line therapy for NSCLC with PET assessment of response Journal of Clinical Oncology. 23: 7299-7299. DOI: 10.1200/Jco.2005.23.16_Suppl.7299 |
0.356 |
|
| 2005 |
Choong N, Mauer A, Hoffman P, Ma P, Cohen E, Rudin C, Kozloff M, Sciortino D, Szeto L, Vokes E. P-473 Phase II trial of temozolomide and innotecan as second-linetreatment for advance non-small cell lung cancer Lung Cancer. 49: S241. DOI: 10.1016/S0169-5002(05)80966-3 |
0.41 |
|
| 2004 |
VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Molecular Cancer Therapeutics. 3: 1605-13. PMID 15634654 |
0.662 |
|
| 2004 |
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Research. 64: 3892-9. PMID 15172999 DOI: 10.1158/0008-5472.Can-03-2904 |
0.791 |
|
| 2004 |
Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 15: 915-20. PMID 15151948 DOI: 10.1093/ANNONC/MDH215 |
0.357 |
|
| 2004 |
Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1110-7. PMID 15020613 DOI: 10.1200/Jco.2004.10.148 |
0.774 |
|
| 2004 |
Ross HJ, Rudin CM, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, Miller DM. Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 22: 7039-7039. DOI: 10.1200/JCO.2004.22.90140.7039 |
0.33 |
|
| 2003 |
Hagan CR, Sheffield RF, Rudin CM. Human Alu element retrotransposition induced by genotoxic stress. Nature Genetics. 35: 219-20. PMID 14578886 DOI: 10.1038/Ng1259 |
0.691 |
|
| 2003 |
Carthy CM, Yanagawa B, Luo H, Granville DJ, Yang D, Cheung P, Cheung C, Esfandiarei M, Rudin CM, Thompson CB, Hunt DW, McManus BM. Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection. Virology. 313: 147-57. PMID 12951029 DOI: 10.1016/S0042-6822(03)00242-3 |
0.363 |
|
| 2003 |
Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, Vokes EE. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 39: 191-6. PMID 12581572 DOI: 10.1016/S0169-5002(02)00447-6 |
0.367 |
|
| 2003 |
Karnauskas R, Niu Q, Talapatra S, Plas DR, Greene ME, Crispino JD, Rudin CM. Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo. Oncogene. 22: 688-98. PMID 12569361 DOI: 10.1038/Sj.Onc.1206159 |
0.775 |
|
| 2003 |
Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Research. 63: 312-8. PMID 12543781 |
0.675 |
|
| 2003 |
Mauer AM, Otterson GA, Winegarden JD, Rudin CM, Villalona MA, Szeto L, Hoffman PC, Vokes EE. P-533 Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer Lung Cancer. 41: S226. DOI: 10.1016/s0169-5002(03)92500-1 |
0.31 |
|
| 2003 |
Winegarden JD, Rudin CM, Mauer AM, Hoffman P, Szeto L, Eileen Dolan M, Vokes EE. P-3 A phase II trial of the combination of temozolomide and irinotecan as second-line therapy for patients with non-small cell lung cancer Lung Cancer. 41: S91-S92. DOI: 10.1016/S0169-5002(03)91972-6 |
0.301 |
|
| 2003 |
Vokes E, Szeto L, Mauer A, Krauss S, Rudin C, Kayitalire L, Hoffman P, Haraf D. O-308 A phase I trial of pemetrexed + chest radiotherapy in patients with advanced or metastatic non-small-cell lung cancer or esophageal cancer Lung Cancer. 41: S89-S90. DOI: 10.1016/S0169-5002(03)91966-0 |
0.436 |
|
| 2003 |
Mauer AM, Harat DC, Rudin CM, Krauss SM, Vokes EE. O-307 A two-arm phase I study of OSI-774 in combination with chemoradiation for patients with unresectable, locally advanced non-small cell lung cancer Lung Cancer. 41: S89. DOI: 10.1016/S0169-5002(03)91965-9 |
0.304 |
|
| 2003 |
Ross H, Rudin CM, Figlin RA, Hart L, Rarick M, Jacobs A, Grove L, Sandler AS, Siegall C, Sing AP. O-150 A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel in patients with advanced stage or metastatic non-small cell lung cancer (NSCLC) Lung Cancer. 41: S46. DOI: 10.1016/S0169-5002(03)91808-3 |
0.301 |
|
| 2002 |
Vander Heiden MG, Choy JS, VanderWeele DJ, Brace JL, Harris MH, Bauer DE, Prange B, Kron SJ, Thompson CB, Rudin CM. Bcl-x(L) complements Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to oxidative metabolism. The Journal of Biological Chemistry. 277: 44870-6. PMID 12244097 DOI: 10.1074/Jbc.M204888200 |
0.764 |
|
| 2002 |
Hagan CR, Rudin CM. Mobile genetic element activation and genotoxic cancer therapy: potential clinical implications. American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice. 2: 25-35. PMID 12083952 DOI: 10.2165/00129785-200202010-00003 |
0.698 |
|
| 2002 |
Zhou R, Vander Heiden MG, Rudin CM. Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Research. 62: 3515-20. PMID 12067998 |
0.63 |
|
| 2002 |
Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 13: 539-45. PMID 12056703 DOI: 10.1093/annonc/mdf124 |
0.35 |
|
| 2001 |
Rudin CM, Thompson CB. Transcriptional activation of short interspersed elements by DNA-damaging agents. Genes, Chromosomes & Cancer. 30: 64-71. PMID 11107177 DOI: 10.1002/1098-2264(2000)9999:9999<::Aid-Gcc1066>3.0.Co;2-F |
0.395 |
|
| 2000 |
Schor NF, Rudin CM, Hartman AR, Thompson CB, Tyurina YY, Kagan VE. Cell line dependence of Bcl-2-induced alteration of glutathione handling. Oncogene. 19: 472-6. PMID 10656697 DOI: 10.1038/sj.onc.1203324 |
0.45 |
|
| 2000 |
Mauer A, Haraf D, Rudin C, Vokes E. A phase I/II study of induction irinotecan (I), paclitaxel (P), and carboplatin (C) followed by concurrent thoracic (TXT) radiotherapy with irinotecan, paclitaxel, and carboplatin in unresectable, locally advanced non-small cell lung cancer (NSCLC) Lung Cancer. 29: 114. DOI: 10.1016/S0169-5002(00)80377-3 |
0.305 |
|
| 2000 |
Cohen E, Hoffman P, Masters G, Daniel H, Mauer A, Rudin C, Watson S, Szeto L, Booda M, Vokes E. Phase I study of carboplatin and vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer Lung Cancer. 29: 105-106. DOI: 10.1016/S0169-5002(00)80347-5 |
0.303 |
|
| 1999 |
Thompson CB, Rathmell JC, Frauwirth KA, Lindsten T, Rudin CM, Opferman JT, Ashton-Rickardt PG, Harris MH, Chandel NS, Schumacker PT, Vander Heiden MG. What keeps a resting T cell alive? Cold Spring Harbor Symposia On Quantitative Biology. 64: 383-7. PMID 11232311 DOI: 10.1101/Sqb.1999.64.383 |
0.654 |
|
| 1999 |
Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer. 85: 164-70. PMID 9921989 DOI: 10.1002/(SICI)1097-0142(19990101)85:1<164::AID-CNCR23>3.0.CO;2-Q |
0.449 |
|
| 1998 |
Dragovich T, Rudin CM, Thompson CB. Signal transduction pathways that regulate cell survival and cell death. Oncogene. 17: 3207-13. PMID 9916983 DOI: 10.1038/Sj.Onc.1202587 |
0.423 |
|
| 1997 |
Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annual Review of Medicine. 48: 267-81. PMID 9046961 DOI: 10.1146/Annurev.Med.48.1.267 |
0.43 |
|
| 1996 |
Rudin CM, Van Dongen J, Thompson CB. Apoptotic signaling in lymphocytes. Current Opinion in Hematology. 3: 35-40. PMID 9372049 DOI: 10.1097/00062752-199603010-00006 |
0.419 |
|
| 1995 |
Minn A, Rudin C, Boise L, Thompson C. Expression of bcl-xL can confer a multidrug resistance phenotype Blood. 86: 1903-1910. DOI: 10.1182/Blood.V86.5.1903.Bloodjournal8651903 |
0.483 |
|
| 1992 |
Rudin CM, Storb U. Two conserved essential motifs of the murine immunoglobulin lambda enhancers bind B-cell-specific factors. Molecular and Cellular Biology. 12: 309-20. PMID 1729607 DOI: 10.1128/Mcb.12.1.309 |
0.546 |
|
| 1990 |
Hagman J, Rudin CM, Haasch D, Chaplin D, Storb U. A novel enhancer in the immunoglobulin lambda locus is duplicated and functionally independent of NF kappa B. Genes & Development. 4: 978-92. PMID 2116989 DOI: 10.1101/Gad.4.6.978 |
0.552 |
|
| 1989 |
Hagman J, Lo D, Doglio LT, Hackett J, Rudin CM, Haasch D, Brinster R, Storb U. Inhibition of immunoglobulin gene rearrangement by the expression of a lambda 2 transgene. The Journal of Experimental Medicine. 169: 1911-29. PMID 2499652 DOI: 10.1084/Jem.169.6.1911 |
0.576 |
|
| Show low-probability matches. |